Supply of meloxicam (MOBIC) 7.5 mg tablet blister pack and meloxicam (MOBIC) 15 mg tablet blister pack by Boehringer Ingelheim Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, governs the regulation of therapeutic goods, including medicines, medical devices, and blood. This Act addresses the need for a comprehensive legislative framework to ensure the safety, quality, and efficacy of therapeutic goods available in Australia. The Act was introduced to fill the gap in regulating therapeutic goods to protect public health and safety. The Therapeutic Goods Administration (TGA), an agency within the Department of Health, is responsible for enforcing the Act. On October 23, 2013, the delegate of the Secretary of the Department of Health, under the authority conferred by the Therapeutic Goods Act 1989, granted consent for the supply of meloxicam (MOBIC) 7.5 mg and 15 mg tablet blister packs by Boehringer Ingelheim Pty Ltd. This consent was given to allow the supply of products that do not conform to certain labelling requirements in TGO 69 but includes conditions to mitigate any potential risks to public health and safety. The policy objective is to ensure therapeutic goods are of acceptable quality while allowing flexibility in certain cases to facilitate the supply of necessary medicines.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration under the Commonwealth of Australia’s Department of Health, applies to the regulation of therapeutic goods, which include medicines, medical devices, and other related products. The Act covers entities such as manufacturers, importers, and suppliers of therapeutic goods and applies to the conduct and transactions involving these goods. Its jurisdictional reach is national, impacting all therapeutic goods supplied across Australia. The Act’s scope includes setting standards and regulating the approval, advertising, and monitoring of therapeutic goods to ensure their safety and efficacy. Specific exclusions and exemptions are outlined in various Therapeutic Goods Orders (TGOs), with TGO 69 being particularly relevant in this context as it specifies requirements for the presentation of batch numbers and expiry dates on product labels. This particular consent granted by the delegate of the Secretary, however, provides an exception to certain labelling requirements in TGO 69 for specific batches of meloxicam tablets supplied by Boehringer Ingelheim Pty Ltd, subject to conditions that ensure the essential information is still communicated to the end-users. The application and interpretation of the Act may be further extended or restricted through subordinate instruments, which provide additional regulatory detail and address specific scenarios not covered in the primary legislation.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") regulates the supply and use of therapeutic goods in Australia. Specifically, the Act authorises the Therapeutic Goods Administration (TGA) to grant consent for the supply of therapeutic goods that do not conform with certain standards, as outlined in Section 15. In this case, the Act allows for the supply of meloxicam tablets that do not comply with specific labelling requirements in Therapeutic Goods Order (TGO) 69, but with certain conditions (Section 15(1)). The meloxicam tablets in question are manufactured by Boehringer Ingelheim Pty Ltd and are supplied in blister packs of varying strengths (Section 1(2)). Under this consent, Boehringer Ingelheim Pty Ltd is required to ensure that the meloxicam tablets supplied do not deviate from the previously submitted PM-2013-00510-1-3 dated February 8, 2013, except for the labelling issue concerning the placement of batch number and expiry date prefixes (Section 1(2)). The company must also provide a Dear Pharmacist letter with affected batches, informing them of the circumstances surrounding this consent to supply and reminding patients to keep the blister strips with the outer carton (Section 1(4)). Failure to comply with the conditions set out in the consent or the Act in general may result in various consequences. Under Section 20 of the Act, the Therapeutic Goods Administration has the authority to take enforcement actions, such as issuing infringement notices or seeking court orders, to ensure compliance with the Act and its associated orders. Additionally, any person who contravenes the Act may be subject to fines and/or imprisonment, as outlined in Section 21 of the Act. The maximum penalty for a corporation found guilty of an offence under the Act is $2,100,000, while the maximum penalty for an individual is $210,000 (Section 21). It is important for Boehringer Ingelheim Pty Ltd and other parties governed by the Act to be aware of these obligations and consequences to ensure compliance with the regulatory framework in place to protect public health and safety.